← boardnext 2026-10-07next 2026-10-12next 2026-11-02next 2026-11-13next 2026-11-13next 2026-12-03next 2026-12-29next 2027-01-06next 2027-02-09next 2027-02-28next 2027-03-22next 2027-03-25next 2027-05-10next 2027-05-15next 2027-06-18next 2027-10-16next 2027-11-15next 2027-11-22next 2027-11-29next 2028-01-26next 2028-02-07next 2028-02-27next 2028-04-11next 2028-06-04next 2028-06-28next 2028-12-10next 2029-02-26next 2029-07-25next 2030-02-03next 2030-02-05next 2030-03-28next 2030-09-20next 2032-04-22next 2034-08-14
REGN
Regeneron Pharmaceuticalsdistress 2/10 · well-funded / low risk$642.66-1%today-21% from 52w high
Oncology 4
Lead: Melanoma · est. market ~$10B (approx, global)
Revenue
$3605M
Liquidity
$18540M
Runway
—
Shares 1y
+18%
Price & events
-14.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.3%
1D
-5.3%
1W
+4.0%
1M
-16.0%
3M
-14.5%
6M
+12.9%
1Y
-38.6%
2Y
+10.5%
5Y
+34.2%
All
Overview
- Market Cap
- $60.38B
- Enterprise Value
- $59.41B
- Volume
- 76.71K
- 52 Week Range
- $543 – $812
- Total Shares
- 93.96M
- Float Shares
- 97.67M
- Short %
- 3.52%
- % Held by Insiders
- 2.03%
- % Held by Institutions
- 92.24%
- RVOL
- 0.09x
- Beta
- 0.24
Pipeline stages · 34 programs
dupilumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Ravulizumab, Pozelimab, Cemdisiran
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Cemiplimab, Fianlimab Fixed Dose Combination (FDC)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
REGN7075, Cemiplimab, Platinum-based doublet chemotherapy
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Olatorepatide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
REGN7999
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Alirocumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
89Zr˗DFO˗REGN5054, cemiplimab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
REGN7508, Apixaban
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
REGN5713, REGN5715
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Show all 34 programs · 24 more ▾
fianlimab, cemiplimab, Pemetrexed
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
REGN5668, Cemiplimab, Ubamatamab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Ubamatamab, REGN7075, Sarilumab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
ALN-SOD
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Mibavademab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
REGN-2Cat, Freneslerbart, Mevonlerbart
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
REGN5678, Cemiplimab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Vonsetamig
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pozelimab, Cemdisiran
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
BNT116, Cemiplimab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Odronextamab, Rituximab, Cyclophosphamide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
REGN13335
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Linvoseltamab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
FDC fianlimab, cemiplimab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
REGN7041
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
garetosmab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
DB-OTO
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
REGN22530
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
REGN10597, Cemiplimab
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
BPX-601
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
REGN4336, REGN5678
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
REGN15505, Cemiplimab, REGN4336
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
REGN5093
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
REGV131, LNP1265
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 80 trials · 80 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-10-07 Estimated 50% readout ~2026-12-21 | Phase 3 | Dupilumab | Atopic Dermatitis | — | active not recruiting |
| 2026-10-12 Estimated 50% readout ~2026-12-26 | Phase 3 | Ravulizumab, Pozelimab, Cemdisiran | Paroxysmal Nocturnal Hemoglobinuria | — | active not recruiting |
| 2026-11-02 Estimated 50% readout ~2026-12-17 | Phase 2 | cemiplimab, Fixed Dose Combination (FDC) cemiplimab, fianlimab | Melanoma | — | active not recruiting |
| 2026-11-13 Estimated 50% readout ~2026-12-28 | Phase 1/2 | REGN7075, Cemiplimab, Platinum-based doublet chemotherapy | Advanced Solid Tumors | — | active not recruiting |
| 2026-11-13 Estimated 50% readout ~2026-12-28 | Phase 2 | Olatorepatide | Overweight or Obesity | — | active not recruiting |
Show all 80 trials · 75 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-12-03 Estimated 50% readout ~2027-01-17 | Phase 2 | REGN7999 | Non-Transfusion Dependent Beta-Thalassemia (NTDT) | — | active not recruiting |
| 2026-12-29 Estimated 50% readout ~2027-02-12 | Phase 2 | Alirocumab | Hypercholesterolemia | — | recruiting |
| 2027-01-06 Estimated 50% readout ~2027-02-05 | Phase 1 | 89Zr˗DFO˗REGN5054, cemiplimab | Advanced Solid Tumor, Metastatic Solid Tumor | — | recruiting |
| 2027-02-09 Estimated 50% readout ~2027-03-26 | Phase 2 | REGN7508, REGN9933, Apixaban | Atrial Fibrillation (AF) | — | recruiting |
| 2027-02-20 Estimated 50% readout ~2027-05-06 | Phase 3 | REGN7508, Apixaban, Enoxaparin | Venous Thromboembolism (VTE) | — | recruiting |
| 2027-02-28 Estimated 50% readout ~2027-05-14 | Phase 3 | REGN5713, REGN5715 | Allergic Conjunctivitis | — | recruiting |
| 2027-03-22 Estimated 50% readout ~2027-06-05 | Phase 3 | fianlimab, cemiplimab, relatlimab | Melanoma | — | recruiting |
| 2027-03-25 Estimated 50% readout ~2027-05-09 | Phase 1/2 | REGN5668, Cemiplimab, Ubamatamab | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer | — | recruiting |
| 2027-05-10 Estimated 50% readout ~2027-06-24 | Phase 1/2 | Ubamatamab, Cemiplimab, Sarilumab | Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer, Endometrial Cancer, Low-grade Serous Ovarian Cancer | — | recruiting |
| 2027-05-15 Estimated 50% readout ~2027-06-29 | Phase 1/2 | ALN-CIDEB | Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis | — | recruiting |
| 2027-05-17 Estimated 50% readout ~2027-07-31 | Phase 3 | REGN7508, Acetylsalicylic Acid (ASA) | Symptomatic Venous Thromboembolism (VTE) | — | recruiting |
| 2027-05-20 Estimated 50% readout ~2027-07-04 | Phase 2 | Cemiplimab, Platinum-based chemotherapy, REGN7075 | Non-Small Cell Lung Cancer | — | recruiting |
| 2027-06-18 Estimated 50% readout ~2027-09-01 | Phase 3 | Mibavademab | Monogenic Obesity | — | recruiting |
| 2027-08-10 Estimated 50% readout ~2027-09-24 | Phase 1/2 | ALN-PNP | Healthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | — | recruiting |
| 2027-08-20 Estimated 50% readout ~2027-10-04 | Phase 2 | Mibavademab | Functional Hypothalamic Amenorrhea (FHA) | — | recruiting |
| 2027-09-24 Estimated 50% readout ~2027-11-08 | Phase 2 | ALN-ANG3, Evinacumab | Diabetic Kidney Disease (DKD) | — | recruiting |
| 2027-09-28 Estimated 50% readout ~2027-12-12 | Phase 2/3 | fianlimab, cemiplimab | Advanced Non-Small Cell Lung Cancer | — | active not recruiting |
| 2027-09-30 Estimated 50% readout ~2027-10-30 | Phase 1 | Cemiplimab, Ipilimumab, Platinum-doublet chemotherapy | Advanced Malignancies | — | active not recruiting |
| 2027-10-16 Estimated 50% readout ~2027-12-30 | Phase 3 | REGN-2Cat, Freneslerbart, Mevonlerbart | Allergic Conjunctivitis | — | not yet recruiting |
| 2027-11-15 Estimated 50% readout ~2027-12-30 | Phase 1/2 | REGN5678, Cemiplimab | Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC) | — | recruiting |
| 2027-11-22 Estimated 50% readout ~2028-01-06 | Phase 1/2 | Vonsetamig | Chronic Kidney Disease (CKD) | — | active not recruiting |
| 2027-11-29 Estimated 50% readout ~2028-02-12 | Phase 3 | Pozelimab, Cemdisiran | Age-related Macular Degeneration (AMD), Geographic Atrophy (GA) | — | recruiting |
| 2028-01-07 Estimated 50% readout ~2028-03-22 | Phase 3 | Cemiplimab | Cutaneous Squamous Cell Carcinoma | — | active not recruiting |
| 2028-01-26 Estimated 50% readout ~2028-03-11 | Phase 2 | BNT116, Cemiplimab | Advanced Non-Small Cell Lung Cancer | — | active not recruiting |
| 2028-02-07 Estimated 50% readout ~2028-04-22 | Phase 3 | Odronextamab, Rituximab, Cyclophosphamide | Follicular Lymphoma (FL) | — | recruiting |
| 2028-02-27 Estimated 50% readout ~2028-04-12 | Phase 2 | REGN13335 | Pulmonary Arterial Hypertension (PAH) | — | recruiting |
| 2028-03-30 Estimated 50% readout ~2028-06-13 | Phase 3 | Odronextamab, Rituximab, Cyclophosphamide | Diffuse Large B-cell Lymphoma (DLBCL) | — | recruiting |
| 2028-04-11 Estimated 50% readout ~2028-05-11 | Phase 1 | Linvoseltamab, Daratumumab, Carfilzomib | Multiple Myeloma | — | recruiting |
| 2028-04-27 Estimated 50% readout ~2028-06-11 | Phase 2 | ALN-HSD | Metabolic Dysfunction-Associated SteatoHepatitis (MASH) | — | recruiting |
| 2028-05-16 Estimated 50% readout ~2028-07-30 | Phase 3 | Fianlimab, Cemiplimab, Pembrolizumab | Melanoma | — | active not recruiting |
| 2028-05-19 Estimated 50% readout ~2028-08-02 | Phase 3 | Mibavademab | Generalized Lipodystrophy | — | recruiting |
| 2028-05-29 Estimated 50% readout ~2028-08-12 | Phase 3 | Odronextamab, Ifosfamide, Carboplatin | B-Cell Non-Hodgkin Lymphoma (B-NHL) | — | active not recruiting |
| 2028-06-04 Estimated 50% readout ~2028-07-19 | Phase 2 | FDC fianlimab, cemiplimab | Head and Neck Squamous Cell Carcinoma (HNSCC) | — | recruiting |
| 2028-06-19 Estimated 50% readout ~2028-09-02 | Phase 3 | dupilumab | Eosinophilic Esophagitis (EoE) | — | recruiting |
| 2028-06-28 Estimated 50% readout ~2028-08-12 | Phase 1/2 | REGN7041 | Active Noninfectious Uveitis Affecting the Posterior Segment | — | active not recruiting |
| 2028-08-20 Estimated 50% readout ~2028-10-04 | Phase 1/2 | Linvoseltamab | Relapsed/Refractory Systemic Light Chain Amyloidosis | — | recruiting |
| 2028-10-30 Estimated 50% readout ~2028-12-14 | Phase 2 | Ubamatamab, Bevacizumab, Cemiplimab | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer | — | recruiting |
| 2028-12-10 Estimated 50% readout ~2029-02-23 | Phase 3 | garetosmab | Fibrodysplasia Ossificans Progressiva (FOP) | — | not yet recruiting |
| 2029-01-23 Estimated 50% readout ~2029-04-08 | Phase 3 | Odronextamab, Lenalidomide, Rituximab | Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) | — | recruiting |
| 2029-02-06 Estimated 50% readout ~2029-03-23 | Phase 2 | ALN-CIDEB | Metabolic Dysfunction-Associated Steatohepatitis (MASH) | — | not yet recruiting |
| 2029-02-16 Estimated 50% readout ~2029-03-18 | Phase 1 | Odronextamab, REGN5837 | B-cell Non-Hodgkins Lymphoma (B-NHL) | — | recruiting |
| 2029-02-26 Estimated 50% readout ~2029-05-12 | Phase 3 | Pozelimab, Cemdisiran | Paroxysmal Nocturnal Hemoglobinuria | — | recruiting |
| 2029-02-26 Estimated 50% readout ~2029-04-12 | Phase 1/2 | DB-OTO | Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) | — | recruiting |
| 2029-03-28 Estimated 50% readout ~2029-06-11 | Phase 3 | REGN7508, REGN9933 | Atrial Fibrillation (AF) | — | recruiting |
| 2029-05-21 Estimated 50% readout ~2029-08-04 | Phase 3 | Linvoseltamab, Carfilzomib, Daratumumab | Relapsed and/or Refractory Multiple Myeloma (RRMM) | — | recruiting |
| 2029-07-25 Estimated 50% readout ~2029-09-08 | Phase 1/2 | REGN22530 | Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT) | — | not yet recruiting |
| 2029-07-29 Estimated 50% readout ~2029-10-12 | Phase 3 | Odronextamab, Rituximab, Cyclophosphamide | Follicular Lymphoma (FL) | — | active not recruiting |
| 2029-08-18 Estimated 50% readout ~2029-11-01 | Phase 3 | REGN7508, REGN9933, Rivaroxaban | Peripheral Artery Disease (PAD) | — | recruiting |
| 2029-09-11 Estimated 50% readout ~2029-11-25 | Phase 3 | REGN7508, Apixaban | Atrial Fibrillation (AF) | — | not yet recruiting |
| 2029-10-10 Estimated 50% readout ~2029-11-24 | Phase 2 | Fianlimab, cemiplimab | Melanoma | — | enrolling by invitation |
| 2029-11-29 Estimated 50% readout ~2030-01-13 | Phase 1/2 | ALN-CFB | Paroxysmal Nocturnal Hemoglobinuria (PNH), Persistent Anemia | — | recruiting |
| 2030-01-16 Estimated 50% readout ~2030-04-01 | Phase 2/3 | fianlimab, cemiplimab, Pemetrexed | Non-small Cell Lung Cancer | — | active not recruiting |
| 2030-01-18 Estimated 50% readout ~2030-04-03 | Phase 3 | Pozelimab, Cemdisiran | Paroxysmal Nocturnal Hemoglobinuria | — | recruiting |
| 2030-01-23 Estimated 50% readout ~2030-04-08 | Phase 3 | REGN7508 | Cancer-Associated Thrombosis (CAT) | — | recruiting |
| 2030-02-03 Estimated 50% readout ~2030-03-20 | Phase 1/2 | REGN10597, Cemiplimab | Melanoma, Clear-Cell Renal-Cell Carcinoma (ccRCC), Advanced Solid Tumors | — | recruiting |
| 2030-02-05 Estimated 50% readout ~2030-03-07 | Phase 1 | BPX-601 | Prostate Cancer | — | recruiting |
| 2030-03-15 Estimated 50% readout ~2030-04-29 | Phase 2 | ALN-PNP, Tirzepatide | Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | — | recruiting |
| 2030-03-28 Estimated 50% readout ~2030-05-12 | Phase 1/2 | REGN4336, REGN5678 | Metastatic Castration-resistant Prostate Cancer | — | recruiting |
| 2030-05-03 Estimated 50% readout ~2030-07-17 | Phase 3 | Cemiplimab | Cutaneous Squamous Cell Carcinoma (CSCC) | — | recruiting |
| 2030-05-27 Estimated 50% readout ~2030-06-26 | Phase 1 | Cemiplimab, Bevacizumab | Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer | — | recruiting |
| 2030-06-24 Estimated 50% readout ~2030-08-08 | Phase 2 | Ubamatamab, REGN7075, Sarilumab | Advanced/Metastatic Non-Small Cell Lung Cancer | — | recruiting |
| 2030-09-20 Estimated 50% readout ~2030-11-04 | Phase 1/2 | REGN15505, Cemiplimab, REGN4336 | Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC) | — | not yet recruiting |
| 2031-07-08 Estimated 50% readout ~2031-09-21 | Phase 3 | REGN7508, Apixaban | Venous Thromboembolism (VTE) | — | recruiting |
| 2032-03-21 Estimated 50% readout ~2032-05-05 | Phase 1/2 | ALN-SOD | Amyotrophic Lateral Sclerosis (ALS), Mutation in the Superoxide Dismutase-1 (SOD1) Gene | — | recruiting |
| 2032-04-22 Estimated 50% readout ~2032-06-06 | Phase 1/2 | REGN5093 | NSCLC | — | recruiting |
| 2032-05-18 Estimated 50% readout ~2032-07-02 | Phase 2 | Linvoseltamab | Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM) | — | recruiting |
| 2032-08-27 Estimated 50% readout ~2032-10-11 | Phase 1/2 | Cemiplimab, Fianlimab Fixed Dose Combination (FDC) | High-Grade Glioma (HGG), Posterior Fossa-A Ependymoma | — | not yet recruiting |
| 2033-01-25 Estimated 50% readout ~2033-03-11 | Phase 2 | Linvoseltamab | Smoldering Multiple Myeloma (SMM) | — | active not recruiting |
| 2033-03-30 Estimated 50% readout ~2033-05-14 | Phase 1/2 | Linvoseltamab | Multiple Myeloma | — | recruiting |
| 2033-04-19 Estimated 50% readout ~2033-07-03 | Phase 3 | Linvoseltamab, Elotuzumab, Pomalidomide | Relapsed Refractory Multiple Myeloma (RRMM) | — | recruiting |
| 2033-07-27 Estimated 50% readout ~2033-10-10 | Phase 3 | Linvoseltamab, Daratumumab | High Risk Smoldering Multiple Myeloma (HR-SMM) | — | recruiting |
| 2033-09-30 Estimated 50% readout ~2033-11-14 | Phase 1/2 | Linvoseltamab, REGN17372 | Relapsed Refractory Multiple Myeloma (RRMM) | — | recruiting |
| 2033-11-11 Estimated 50% readout ~2033-12-26 | Phase 1/2 | Linvoseltamab, REGN7945 | Relapsed/Refractory Multiple Myeloma | — | recruiting |
| 2034-08-14 Estimated 50% readout ~2034-09-28 | Phase 1/2 | REGV131, LNP1265 | Hemophilia B | — | recruiting |
| 2035-11-02 Estimated 50% readout ~2035-12-17 | Phase 1/2 | Linvoseltamab | Multiple Myeloma | — | recruiting |
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (9)
- LYNOZYFICLINVOSELTAMAB-GCPT2025 · Prescription
- VEOPOZPOZELIMAB-BBFG2023 · Prescription
- EYLEA HDAFLIBERCEPT2023 · Prescription
- EVKEEZAEVINACUMAB-DGNB2021 · Prescription
- INMAZEBATOLTIVIMAB2020 · Prescription
- LIBTAYOCEMIPLIMAB-RWLC2018 · Prescription
- DUPIXENTDUPILUMAB2017 · Prescription
- PRALUENTALIROCUMAB2015 · Prescription
- EYLEAAFLIBERCEPT2011 · Prescription
Capital structure — dilution & financing
Shares out: 93,955,110 · 0 offerings/1y · 0 PIPEs
- 2024-10-31S-3ASRshelf_registration
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $819 (+27% upside) · 26 analysts
- 2026-07-21GuggenheimBuy
- 2026-07-09Piper SandlerOverweight
- 2026-07-08Morgan StanleyEqual-Weight
- 2026-07-07Truist SecuritiesBuy
- 2026-07-07RBC CapitalSector Perform
- 2026-07-07BenchmarkHold → Buy
Competitors — Melanoma
- NVSEFNOVARTIS AG$292.0B · D3
- IDYAIDEAYA Biosciences, Inc.$3.0B · D3
- IOVAIOVANCE BIOTHERAPEUTICS, INC.$2.3B · D4
- IMCRImmunocore Holdings plc$1.8B · D1
- REPLReplimune Group, Inc.$906M · D2
- AURAAura Biosciences, Inc.$722M · D6
- CATXPerspective Therapeutics, Inc.$334M · D5
- IMRXImmuneering Corp$112M · D3
- PHIOPhio Pharmaceuticals Corp.$12M · D7
- IOBTQIO Biotech, Inc.$71,949 · D5
Recent news
- 2026-07-23SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN - PR Newswire
- 2026-07-23REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky - Business Wire
- 2026-07-23INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - REGN - PR Newswire
- 2026-07-23Did You Lose Money Investing in Regeneron Pharmaceuticals, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against REGN - TMX Newsfile
- 2026-07-23Here's What to Expect From Regeneron Pharmaceuticals’ Next Earnings Report - Barchart.com
- 2026-07-23REGN INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026 - Eagle-Tribune
- 2026-07-23REGN INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026 - Business Wire
- 2026-07-22Regeneron Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.